reports
Medigene AG Expands Patent Portfolio with European Patent Grant for it...
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor Planegg/Martinsried, May 2, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis antigen, which is expressed in multi...
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a ...
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein Planegg/Martinsried, May 2, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presented superior T cell receptor engineered T (TCR-T) cell functionality upon combination of optimal affinity 3S (sensitive, specific and safe) TCRs with the PD1-41BB costimulatory switch protein (CSP) at the 7th International Neoantigen Summit held in Amsterdam, Netherlands from A...
Medigene AG reports Financial Results and Business Update for Q1 2024
Medigene AG reports Financial Results and Business Update for Q1 2024 Planegg/Martinsried, April 26, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the first quarter of 2024. The full Quarterly Statement Q1 2024 can be downloaded here: . "During the first quarter of 2024, our focus remained on executing our strategic plan and advancing the development of our unique TCR-T therapies for solid tumors, such as our lead p...
Medigene presents streamlined 6-day, high stemness TCR-T therapy prod...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process Planegg/Martinsried, April 25, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents a comprehensive overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell (TCR-T) therapy, at CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London. MDG1015, which is advancing towards the clinic, targets ...
Medigene to Present at Upcoming Scientific Conferences
Medigene to Present at Upcoming Scientific Conferences (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the conferences: Oral presentation: CHI's 8th Annual ...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimu...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024 Planegg/Martinsried, April 8, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cance...
Medigene AG Secures European Patent for its iM-TCR Technology
Medigene AG Secures European Patent for its iM-TCR Technology Planegg/Martinsried, April 4, 2024. (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapies. “Over the past years we have conscientio...
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corp...
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program MDG1015 with IND/CTA approval expected in 2H 2024 Partnering expansion with new scientific partnership with the National Cancer Institute and further collaboration for new costimulatory switch protein with Helmholtz MunichUpdates to strategy going forward to develop both TCR-T therapies and additional, non-autol...
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Ther...
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024. Members of Medigene's management team will join a fireside chat and will be available for virtual one-on-one meetings with registered investors. --- end of press rele...
Medigene AG to report full year 2023 financial results on March 28, 2...
Medigene AG to report full year 2023 financial results on March 28, 2024 Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024. Following the release of the full year 2023 earnings results and annual report on Medigene’s website, the Company will host a conference call that same day at 3 pm CET / 10 am ET. Full deta...
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addit...
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting Planegg/Martinsried, March 6, 2024. (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held...
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to...
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo Planegg/Martinsried, March 4, 2024. (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. “We are delighte...
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach ...
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty Crame, Vice President, Clinical Strategy & DevelopmentPresentations and seminars highlight key parts of Medigene’s proprietary End-to-End Platform by offering multiple solutions to address the challenges in TCR-T therapy development for treatment of solid tumors Planegg/Martinsrie...
Medigene to Present at Upcoming Conferences
Medigene to Present at Upcoming Conferences Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024 Presentation Date: February 28, 2024, 5:30 pm local timeLocation: London, UKPresenter: Prof...
Medigene Announces Indication Selection for the Clinical Development ...
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB Clinical development in both orphan and more common cancer indications addresses high unmet medical need in large patient populations Planegg/Martinsried, Febru...
Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Confer...
Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference Planegg/Martinsried, December 19, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco to be held from January 8-11, 2024. J.P. Morgan Healthcare Conference Date: January 8-11, 2024Location: The Westin St. Francis Hotel, San Francisco, CA Members of Medigene’s management team will...
Medigene AG Announces Prioritization of Pipeline and Resource Allocati...
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway Lead program MDG1015 on track for CTA/IND approval in 2H 2024Prioritization of pipeline to accelerate the advancement of Medigene’s maturing KRAS-libraryProjected cash runway extended to Q1 2025. Exploring financing options to extend cash runway into 2026 and beyond Planegg/Martinsried, November 21, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies fo...
Medigene amends 2023 financial guidance
Medigene amends 2023 financial guidance Planegg/Martinsried, November 21, 2023 The Executive Management Board of Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2023. The Company maintains its guidance on expected revenues to be between EUR 5 and 7 million in 2023 (unchanged). The Company continuously optimizes its resource allocation based on business demands. Due to the challenging capital m...
Medigene presents new data for MDG2011, the first TCR in a novel KRAS ...
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11 Planegg/Martinsried, November 4, 2023. (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents novel preclinical data of their MDG2011 program lead candidates which are optimal affinity Kirsten rat sarcoma viral oncogene homologue mutation (mKRAS)-specific T ce...
Medigene Reports Financial Results and Corporate Update for Q3 2023
Medigene Reports Financial Results and Corporate Update for Q3 2023 Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for technologies in our End-to-End Platform Guidance confirmed; cash runway maintained through Q4 2024 Planegg/Martinsried, October 26, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.